Welcome to the 6th Obesity & NASH Drug Development Summit
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2023 event, please get in touch at email@example.com
Putting a spotlight on exciting pathways for therapeutic intervention, leveraging robust preclinical tools to predict efficacy, and moving the needle on alternatives to weight loss surgery
The 6th Obesity & NASH Drug Development Summit (previously known as NASH Summit) is uniquely positioned to de-risk drug development in metabolic disorders and provide strategic insight into paving the way to regulatory approval.
Hear from industry experts unravelling mechanisms of injury and repair, establishing a clinical pathway to validate imaging markers and other non-invasive biomarkers for diagnosis and disease monitoring, and leading the charge in unparalleled trial design to bring effective therapies to patients faster.
Unmissable highlights for 2022:
Forge a deeper understanding of multifactorial pathogenesis of NASH and interrogate the interrelationships between obesity, cardiometabolism and NAFLD with Inventiva, Mitotherapeutix, and Bayer to investigate exciting opportunities for therapeutic intervention
Define the next step in developing and validating early biomarkers of therapeutic efficacy and investigate disease specific endpoint development with AstraZeneca, FDA, and the National Institutes of Health to investigate the reliability and reproducibility of non-invasive biomarkers and drive more standardized and accurate understanding of disease progression
Reimagine patient inclusion and exclusion criteria through strategic consideration of disease stage and comorbidities with Boehringer Ingelheim, Empros Pharma, and Altimmune to transform patient recruitment
Navigate exciting progress in leveraging GLP-1 receptor agonists in novel ways and the latest updates in combination therapy in obesity and NASH with Novo Nordisk, Eli Lilly, and Pfizer to elucidate pathways to clinical success
Investigate organ system crosstalk and opportunities for indication expansion across metabolic disorders with Gilead, Glyscend, and Ridgeline Therapeutics to target multi-factorial disease pathogenesis and gain a holistic perspective on comorbidities and treatment